Crosseal Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical validation of fibrin sealants, rising surgical procedure volumes, demand for improved bleeding control, hospital adoption of advanced hemostatic agents, regulatory approvals for surgical sealants.

The growth in the forecast period can be attributed to growth in orthopedic and cardiac surgeries, expansion of outpatient surgical centers, rising preference for biologic sealants, technological advances in tissue adhesives, aging population requiring surgeries. Major trends in the forecast period include increasing use of fibrin sealants in surgery, growing focus on surgical hemostasis, expansion of minimally invasive surgical procedures, rising adoption of biological tissue adhesives, improved outcomes in complex surgical interventions.

The rising number of injuries is expected to drive the growth of the Crosseal market in the coming years. Injuries refer to physical harm or damage to the body caused by external forces, trauma, or adverse events such as accidents, falls, or violence. This increase is fueled by factors such as urbanization, higher road traffic, unsafe work environments, lifestyle changes, and rising instances of violence and natural disasters. Crosseal supports patients with injuries by providing advanced tissue-sealing solutions that promote rapid hemostasis, reduce surgical complications, and facilitate faster recovery, improving overall treatment outcomes. For example, in May 2025, Transport Canada, a Canada-based government agency, reported that motor vehicle fatalities in 2023 reached 1,964, representing a 1.7% increase from 1,931 deaths in 2022. Consequently, the rising number of injuries is driving the growth of the Crosseal market.

The increasing healthcare spending is expected to support the expansion of the Crosseal market. Healthcare spending refers to total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at improving individual and population health. This growth is driven by an aging population, advancements in medical technology, rising prevalence of chronic diseases, and higher demand for healthcare services. Increased healthcare spending benefits Crosseal by highlighting the need for effective hemostatic agents to enhance surgical outcomes and support efficient healthcare delivery. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022, reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare spending is driving the growth of the Crosseal market.

The growing number of minimally invasive surgeries is expected to further propel the growth of the Crosseal market. Minimally invasive surgeries (MIS) are procedures performed through small incisions or natural body openings using specialized instruments, minimizing damage to surrounding tissues. The increasing adoption of MIS is driven by advancements in medical technology and a rising patient preference for procedures that offer shorter recovery times and reduced post-operative pain. Crosseal enhances these procedures by ensuring efficient hemostasis, minimizing bleeding risks, and promoting faster healing, leading to better patient outcomes and streamlined surgical workflows. For example, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, reported that the total number of cosmetic minimally invasive procedures increased from 23.7 million in 2022 to 25.4 million in 2023. Consequently, the rising number of minimally invasive surgeries is driving the growth of the Crosseal market.

Major companies operating in the crosseal market are Omrix Biopharmaceuticals Inc.

North America was the largest region in the crosseal market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crosseal market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crosseal market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the crosseal market by increasing costs associated with plasma derived components, sterile manufacturing, and surgical supply distribution. These impacts are most visible in hospital pharmacies and surgical supply chains. Higher tariffs have added cost pressure on advanced surgical products. At the same time, tariffs are encouraging regional production of biologic sealants. This is strengthening long term supply security for fibrin sealant products.

The crosseal market research report is one of a series of new reports that provides crosseal market statistics, including crosseal industry global market size, regional shares, competitors with a crosseal market share, detailed crosseal market segments, market trends and opportunities, and any further data you may need to thrive in the crosseal industry. This crosseal market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Crosseal is a brand of fibrin sealant, a biological adhesive used to control bleeding and support tissue healing during surgical procedures. It is composed of fibrinogen and thrombin, which, when combined, replicate the final steps of natural blood clotting, forming a clot to seal tissue and stop bleeding.

The main types of Crosseal include fibrin sealants, synthetic sealants, and hemostatic agents. Fibrin sealants are biological adhesives made from fibrinogen and thrombin that promote clotting. They are used in surgeries such as orthopedic, cardiac, general, liver, and gynecological procedures. Distribution occurs through hospital pharmacies, surgical supply distributors, and outpatient surgery centers.

The crosseal market consists of sales of tissue sealants and biological glues. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.